On October 23, 2015 Cellular Biomedicine Group Inc. (NASDAQ: CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, reported that it would provide a meaningful update on a Phase IIa Trial of it’s CD20 Chimeric Antigen Receptor T-cell (CAR-T) therapy in Advanced, Refractory or Relapsed Diffuse Large B-Cell Lymphoma (DLBCL) at the upcoming 4th International Conference on Translational Medicine to be held on October 26-28, 2015 in Baltimore, Maryland, USA (Press release, Cellular Biomedicine Group, OCT 23, 2015, View Source [SID:1234507846]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Title: Treatment of CD20-directed chimeric antigen receptor-modified T cells in patients with relapsed or refractory B-cell Non-Hodgkin’s lymphoma: An early Phase IIa trial report
Scientific Program: October 26, 2015 16:15-16:40 EDT
Location: DoubleTree by Hilton Hotel Baltimore – BWI Airport, Chesapeake Hall
Presenter: Yihong Yao, Ph.D., Chief Scientific Officer, Cellular Biomedicine Group
Full details of the presented data will be available on the Company’s website following the presentation.